Modality
Multispecific
MOA
BETi
Target
MDM2
Pathway
JAK/STAT
CMLSCLC
Development Pipeline
Preclinical
~Apr 2017
→ ~Jul 2018
Phase 1
Oct 2018
→ May 2028
Phase 1Current
NCT03005355
1,441 pts·CML
2023-09→TBD·Active
NCT08495339
83 pts·CML
2018-10→2028-05·Completed
1,524 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-05-112.1y awayPh2 Data· CML
Trial Timeline
Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
P1/2
Complet…
P1/2
Active
Catalysts
Ph2 Data
2028-05-11 · 2.1y away
CML
ActiveCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03005355 | Phase 1/2 | CML | Active | 1441 | 6MWD |
| NCT08495339 | Phase 1/2 | CML | Completed | 83 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| LLY-6079 | Eli Lilly | Phase 2 | MDM2 | |
| LLY-1592 | Eli Lilly | NDA/BLA | FGFR | |
| LLY-3251 | Eli Lilly | Phase 2 | MDM2 | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| GSK-7987 | GSK | Phase 3 | MDM2 | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| AMG-2752 | Amgen | Preclinical | MDM2 | |
| REG-3155 | Regeneron | Phase 1/2 | MDM2 | |
| BII-1564 | Biogen | Phase 2 | PSMA |